African-Americans Account for Nearly One-Fifth of U.S. Diabetes Population with Notable...

Wed Mar 26, 2008 9:00am EDT

* Reuters is not responsible for the content in this press release.

African-Americans Account for Nearly One-Fifth of U.S. Diabetes Population with Notable Differences in the Group's Profile, According to Study by GfK Market Measures' Roper Global Diabetes Group

   Research Uncovers Growth in Diabetes Rates Among African-American
Population and Notes Compelling Differences in Group's Type 2 Diabetes
Patient Profile Compared to Other Type 2 Patients
EAST HANOVER, N.J.--(Business Wire)--
Nearly 3 million African-Americans are estimated to be diabetic,
representing 17 percent of all diabetes patients in the United States;
and this figure is growing as the proportion of African-American
patients diagnosed with diabetes consistently increases year to year,
according to new research from GfK Market Measures' Roper Global
Diabetes Group.

   A new study of the diabetes market suggests that African-American
patients are being diagnosed at higher rate than other patients.
According to GfK Market Measures' Roper Global Diabetes Group's 2007
U.S. Diabetes Patient Market Study, 14 percent of African-American
diabetes patients were diagnosed with diabetes within the past 12
months compared to 8 percent of other patients. Furthermore, the Roper
U.S. studies have shown that the proportion of African-American
patients diagnosed in the past 12 months has consistently increased,
from 8 percent in 2004 to 14 percent in 2007.

   In comparing the African-American Type 2 diabetes population to
the rest of the Type 2 diabetes population in the United States, the
study uncovers several notable differences between the groups'
demographic, concomitant conditions and therapy profiles. In terms of
age, the African-American diabetes population tends to be younger than
other patients, with 73 percent under age 65 (compared with 57 percent
under age 65 for other patients). It is also important to note that
patients in this group are diagnosed at an earlier age - 47 vs. age 51
for other patients.

   According to the research, African-American patients are more
likely than other patients to suffer from most concomitant conditions
that are typical of the disease. These include cardiovascular
problems, reported by 83 percent of African-Americans compared with 76
percent of other patients. An additional insight is that
African-American patients are significantly more likely to experience
hypertension, with 69 percent reporting high blood pressure compared
with 54 percent of other patients, putting them at greater risk for
heart attack or stroke.

   This group also reports more microvascular complications compared
to other patients (83 percent vs. 78 percent). Finally,
African-American patients are more likely to suffer severe weight
issues, with 64 percent of patients in this group described as obese
or morbidly obese compared with 58 percent of other patients.

   A look at the therapy profile of African-Americans reveals they
are slightly more likely to be treated for their condition compared to
other patients: 27 percent of this group reports treatment with
insulin compared with 24 percent of other patients. Both groups,
however, are equally likely to be treated with non-insulin agents at
nearly 63 percent each. Specific to insulin administration, however,
notable differences again appear in the two diabetes populations.
African-American patients are more likely than other patients to use
disposable syringes (86 percent vs. 78 percent). Correspondingly, the
usage of insulin pens is lower among this population, at 19 percent
compared with 25 percent of other patients. Regarding blood glucose
monitoring, similar proportions of African-Americans and other
patients test for their blood sugar with nearly 87 percent of each
group having tested in the past month. Notably, 9 percent of
African-Americans have never self-tested compared with 4 percent of
other patients.

   "In the African-American patient segment, the need to educate is
critical especially with regard to the relatively widespread
prevalence of conditions such as obesity and high blood pressure, as
is the importance of regular blood glucose monitoring," said David
Jacobson, senior vice president of GfK Market Measures' Roper Global
Diabetes Group. "Like Latinos, this is a fast-growing segment and less
affluent than other U.S. patients, and the relative youth of these
groups may be a factor in their greater reliance on the Internet as
well as on TV, family, friends and other patients for diabetes
information. Overall, our research suggests African-American patients
may require special marketing and communications approaches to reach
them effectively."

   150 African-American Diabetes Patients Share Their Insights

   Reflecting insights from 151 African-American diabetes patients,
fielded via in-depth telephone interviews from July 13 through
September 6, 2007, and as part of a larger, nationally representative
study that included a total of 2,009 diagnosed diabetes patient
respondents, GfK Market Measures' Roper Global Diabetes Group's 2007
U.S. Diabetes Patient Market Study provides a comprehensive
perspective of the diabetes market.

   About GfK Market Measures

   GfK Market Measures provides health care clients with a unique mix
of custom and syndicated research solutions to support the full
marketing continuum. GfK Market Measures is a member of the GfK U.S.
Healthcare Companies, the largest provider of custom health care
marketing research services in the United States. For further
information, visit For more details on this
study or to schedule an interview with a GfK Market Measures
executive, please contact Jessica Makovsky, group vice president of
communications, GfK U.S. Healthcare Companies, at 215.283.3200 x372 or

GfK Market Measures
Jessica Makovsky
Group VP Communications
Tel.: 215-283-3200 x372
Fax: 215-283-3201

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.